to improving the capacity of the existing Unit. It would comprise the following six components â€“ (a) a Pharmacovigilance Technical Committee which works on the collection, quality and validation of data; (b) a Causality Assessment Committee which is responsible for overviewing the data capturing mechanism for reporting of Adverse Drug Reactions and quality issues related to the use of all medicinal products; (c) a new Declaration Form has been published in accordance with the WHO format and